Download MendeleySpiro-Azetidine Oxindoles as Long-Acting Injectables for Pre-Exposure Prophylaxis against Respiratory Syncytial Virus Infections.
Kesteleyn, B., Herschke, F., Darville, N., Stoops, B., Jacobs, T., Jacoby, E., Shaffer, P., Lammens, L., Van Rompaey, D., Matcha, K., Martinez Lamenca, C., Coesemans, E., Hache, G., Pieters, S., Lecomte, M., Hu, L., Demin, S., Milligan, C., Abeywickrema, P., De Bruyn, S., Van Den Berg, J., Ysebaert, N., De Zwart, L., Najera, I., Rigaux, P., Roymans, D., Jonckers, T.H.M.(2024) J Med Chem 67: 10986-11002
- PubMed: 38932487
- DOI: https://doi.org/10.1021/acs.jmedchem.4c00514
- Primary Citation of Related Structures:
9BJM - PubMed Abstract:
Respiratory syncytial virus (RSV) is a major cause of hospitalization in infants, the elderly, and immune-compromised patients. While a half-life extended monoclonal antibody and 2 vaccines have recently been approved for infants and the elderly, respectively, options to prevent disease in immune-compromised patients are still needed. Here, we describe spiro-azetidine oxindoles as small molecule RSV entry inhibitors displaying favorable potency, developability attributes, and long-acting PK when injected as an aqueous suspension, suggesting their potential to prevent complications following RSV infection over a period of 3 to 6 months with 1 or 2 long-acting intramuscular (IM) or subcutaneous (SC) injections in these immune-compromised patients.
Organizational Affiliation:
Janssen Research & Development, Janssen Pharmaceutica NV, Turnhoutseweg 30, Beerse 2340, Belgium.
